SNY: 赛诺菲集团

SNY新闻

• 17:03 AI Bubble Risks Make Dividend Stocks Attractive Again
• 17:02 Stock Market Losses Led By Nasdaq, AI Stocks; Goldman, GE, Taiwan Semi, IBM In Focus: Weekly Review
• 13:12 Merck Snags A First-Of-Its-Kind Approval, And Shares Jump
• 20:48 A Fresh Look At Syndax Pharmaceuticals (NASDAQ:SNDX)
• 18:05 DNLI Stock Surges 59.4% Year to Date: Is There More Room for Growth?
• 13:55 My Top 5 Pharma Stocks Wall Street Ignores
• 14:15 Snowflake Gains 6% in a Month: Should You Buy, Sell, or Hold the Stock?
• 17:06 KYMR Stock Soars 51% YTD on Progress of Atopic Dermatitis Drug
• 13:22 SNY's Nexviazyme Meets Goals in Infantile-Onset Pompe Disease Study
• 17:47 Sanofi Reports Data From Nexviazyme Study, Says It Meets All Endpoints - Sanofi (NASDAQ:SNY)
• 16:34 What Sparked the $43B Jump in AbbVie's Market Cap in the Past Week?
• 13:03 Vertex Pharmaceuticals Has One Of The Widest And Most Durable Moats In Biotech (VRTX)
• 21:00 Big Pharma's Looming Patent Cliff Period And How It Is Trying To Address It (NYSEARCA:XLV)
• 13:04 TG Therapeutics Surged 88%: Time To Be More Careful (Rating Downgrade) (NASDAQ:TGTX)
• 18:39 Healthcare stocks have become a haven for investors ditching tech
• 15:05 Nurix Stock Up 29% in a Month: Here's What You Should Know
• 15:11 Is Kymera Therapeutics The Next Big Rival To Regeneron And Sanofi?
• 18:35 MacroGenics: 'Hold' Potential Best-In-Class B7-H3 ADC And TZIELD Payment (NASDAQ:MGNX)
• 20:30 1 of the Most Interesting AI Stocks in the Market Isn’t a Tech Company
• 18:24 Regeneron's Applications for gMG Drug Accepted by FDA and EMA
• 16:55 Viatris Soared 54%: Time To Be More Careful (Rating Downgrade) (NASDAQ:VTRS)
• 15:44 Merck's Anti-TL1A Antibody Meets Goal in Ulcerative Colitis Study
• 15:24 EU Clears SNY's Cenrifki for Secondary Progressive Multiple Sclerosis
• 14:50 ABBV Jumps on Deepening Immunology Portfolio With $10.9B APGE Buyout